EDIL3 and cardiac hypertrophy: found that endothelial DEL-1 overexpression or recombinant DEL-1 treatment inhibited AGNII or DOCA salt-induced inflammation and MMP2 activation in the heart, thereby reducing cardiac hypertrophy, fibrosis, and dysfunction (41).